The Proposed Changes to NDC System Legacy NDC Numbers and Compliance December 11, 2006 Dr. Thomas F. Willer Director Global Regulatory Affairs.

Slides:



Advertisements
Similar presentations
Drug Information for Consumers and Healthcare Professionals Food and Drug Law Institute Annual Meeting Alan Goldhammer, PhD Associate VP Regulatory Affairs.
Advertisements

INC Report to the NANC January 16, 2001 Norman Epstein INC Moderator.
Unique Device Identification (UDI) System for Medical Devices Dr Larry Kelly Therapeutic Goods Administration.
WHO Good Distribution Practices for Pharmaceutical Products
Structured Product Labeling Overview
Impact of the proposals on the actors of the supply chain : benefit and risk French Federation of Trade and Distribution (FCD)- EuroCommerce 1.
Australian Guidance Document Number xx Cathy Thomas Professional Representation OT Australia WA.
Assures that feed… –has the identity and strength, which it purports –meets the quality, purity, and safety requirements, which it is represented to possess.
ICD-10 Planning and Assessment
Project Advisory Committee Meeting 26th June 2012, New Delhi Vikash Batham CUTS International Exploring the Interplay between Business Regulation and Corporate.
October/November 2007 Federal Deficit Reduction Act (DRA) October/November 2007.
“Paperless Labeling Rule” Proposed Rule First Look January 2015.
ASME Nuclear Conformity Assessment
Inmar CLS MedTurn Pharmaceutical Symposium October 19-20, 2009 Rodney Bias, VP Regulatory.
NDC and CVX Mitra Rocca. NDC  NDC is produced by the Federal Drug Administration (FDA) and serves as a universal product identifier for human drugs.
Christine Simmon Senior Vice President, Policy & Strategic Alliances Generic Pharmaceutical Association November 6, 2014 Biologics Naming.
1 FDA’s Proposed Revised 21 CFR 207 Rule and Electronic Drug Registration and Listing Systems (e-DRLS) John W. Gardner, MD, DrPH Director, DCRMS / OC /
External Defibrillators: Recalls, Inspections, and the Quality System Regulation Melissa Torres Office of Compliance December 15, 2010.
PhRMA Presentation to FDA: Bar Codes to Reduce Medication Errors
Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.
11/2/991 CDER’s 21 CFR Part 11 Implementation Study Greg Brolund Associate Director, Office of Information Technology, CDER/FDA.
1 1 PDUFA & FDA Legislation FDA Regulatory & Compliance Symposium August 2006 Marc Wilenzick, Moderator for Panel: Dan Carpenter, Harvard Dept. of Government.
1 ACPS November 15, Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.
21 CFR Part 11 A Food Industry Perspective FDA Public Meeting June 11, 2004 Sia Economides Center Director Center for Development of Research Policy and.
What You Want to Know About Generic Drugs Generic Drugs: Safe. Effective. FDA-Approved.
DRAFT Guidance for Industry: Providing Regulatory Submissions in Electronic Format – Drug Establishment Registration and Drug Listing Denise Sánchez, J.D.,
Ashland Specialty Ingredients IFAC’s cGMP Audit Guide How the Food Ingredient Industry has Responded to FSMA and Food Safety Audits Priscilla Zawislak.
SupplySide East, April 28, 2009Council for Responsible Nutrition Ingredient Supplier Qualification Implementation of the SIDI™ protocol.
Good Clinical Practice (GCP)- An introduction Dr Noor Ibrahim Mohamed Sakian.
© 2010 Premier, Inc. 9/8/ NAVIGATING THE DRUG SHORTAGE CRISIS IN AMERICAN HEALTHCARE Coleen A. Cherici, RPh, MBA Director of Pharmacy Consulting.
Internet Data Base Information Retrieval Services.
Responsible CarE® Product Stewardship – Building Your Team David Sandidge Director, Responsible Care American Chemistry Council June 2010.
Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT.
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.
Managing Pharmaceutical Reverse Logistics
Global Data Synchronization Major Release MjR Business Value Executive Summary.
EXCiPACT TM EXCiPACT TM International Pharmaceutical Excipients Certification Minimize risks – maximize benefits.
Pharmaceutical Services Guidance Training CFR § , (a)(b)(1) F425.
CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. THE PRACTICE OF REGULATORY INTELLIGENCE: CASE STUDIES OMICS 5 th International Pharmaceutical.
October 8, 2003Ontario Energy Board1 Ontario Energy Board Update E.A. Mills Director – Regulatory Affairs Market Advisory Committee October 8, 2003.
Quality by Design & Question-Based Review: Observations by the Generic Pharmaceutical Industry Advisory Committee for Pharmaceutical Science October 5,
Proposed Gluten Regulations in Argentina Excipient Realities and Global Requirements.
PhRMA Perspective on FDA Final Report FDA Advisory Committee on Pharmaceutical Sciences October 20, 2004 G.P. Migliaccio, Pfizer Inc.
Financial Services Authority New Rules for Trading Companies.
© 2004 Moses & Singer LLP HIPAA and Patient Privacy Issues Raised by the New Medicare Prescription Drug Program National Medicare Prescription Drug Congress.
FDA Regulatory and Compliance Symposium
Final Rule for Preventive Controls for Animal Food 1 THE FUTURE IS NOW.
Major Release 3.1 Global Webinar
Initiatives Drive Pediatric Drug Development January 30, 2002.
Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,
0 Due Diligence Monitoring and Auditing of Third Party Vendors October 28, 2008 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.
International Association of Oil and Gas Producers Stakeholder view of EFET R_ISO Proposal Prague – 21 January 2008.
Experience with NDC Numbers Manufacturer Packager/ Repackager Labeler/ Relabeler Distributor Private Label Distributors Trained by the FDA Participated.
1 Summary of FDA Guidance for Industry Standards for Securing the Drug Supply Chain – Standardized Numerical Identification for Prescription Drug Packages.
© Copyright IBM 2007DIA ERS SIAC Presentation, January 2008 The HL7 RPS and SPL Standards - A High Level View Terry Hardin Sr. IT Architect Emerging Software.
© 2014 GS1 US ALL RIGHTS RESERVED Making a Difference 1.
Clinical Trials.
Dailymed/RxNorm Jamboree Leyla Rahjou-Esfandiary September 2016
Recommended Draft Policy ARIN
The Information Professional’s Role in Product Safety
DISTRIBUTION AND DISTRIBUTION RECORDS
Consideration of Final Rulemaking
American Society for Quality Region 5 Quality Conference
SPL Implementation Working Group Leyla Rahjou-Esfandiary October 2016
Present By:- Company Name: Global Market Forecastes Tel: / Web:
Proposal for a Regulation on medical devices and Proposal for a Regulation on in vitro diagnostic medical devices Key Provisions and GIRP Assessment.
Combination products The paradigm shift
The U.S. Practice of Regulatory Review Food Labeling Case Example
Compounded Drugs and Lack of Premarket FDA-Approval
Presentation transcript:

The Proposed Changes to NDC System Legacy NDC Numbers and Compliance December 11, 2006 Dr. Thomas F. Willer Director Global Regulatory Affairs

2 The National Drug Code National Drug Code (NDC) numbers are one of the lynchpins of the healthcare system NDC numbers are used throughout the drug supply chain Users extend from pharmaceutical firms, distribution system, medical community, insurance industry, and government

3 Current NDC Regulations 21 CFR § –New NDC numbers have three components: Labeler Code: “…the manufacturer or distributor…” Product Code: “…segment that identifies the drug formulation…” Package Code: “…segment that identifies the trade package size and type…” –Labeler code is assigned by FDA, with –Product and Packaging codes assigned by manufacturer.

4 Proposed NDC Rule Universal standard format Drug industry requests new NDC numbers FDA assigns new NDC numbers Current NDC numbers remain unchanged provided that those NDC numbers comply with the new rule when finalized Non-compliant NDC numbers will be reassigned by FDA

5 Impact: Changing NDC Numbers The current NDC numbers identify products that are already in the drug chain Existing NDC numbers may have been in the system for decades and accepted by users

6 Impact: Legacy NDC Numbers Requiring revised NDC codes has significant issues: Industry or the FDA could potentially have to recode thousands of existing products Added characteristic to the Proposed NDC Rule: –New, additional, individual NDC codes for additional levels of packaging: Unit (already exists) Carton (proposed) Corrugate / shipper (proposed)

7 Impact of Any Significant Conversion from Existing NDC Numbers Potential interruption of drug supply Increased cost to healthcare consumers due to shifting of economic burden Industry-government-supply chain costs of maintaining two NDC number systems until “old” numbers pass drug expiration periods Impact on DEA products not addressed in Proposed Rule Increased operational costs due to NDC number reconciliation Millions of dollars in relabeling

8 Proposed NDC Rule Clarifications needed: –What will be considered a “Compliant” NDC number? –How will the 3 year and 9 month implementation period be administered? –What is considered a unique package code? –Has FDA identified its resources to be able to manage a massive NDC number allocation system?

9 Points for Consideration The desire for the government to change legacy NDC numbers is not obvious Legacy NDC numbers currently meet market and gov’t. needs If change is desired, the implementation period should be extended from 3 to 5 years The FDA allocation of NDC numbers must be performed in an expeditious, and known, time period after a request is made There must be confidentiality of NDC requests prior to NDA or ANDA product approvals

10 ISSUES: Companies, Consumers, Regulators New bar codes Bar code reader reprogramming Mergers and Acquisitions Timetable to Compliance New system learning curve Finite pool of NDC numbers Confidentiality Timeliness

Thank You